The treatment of Parkinson’s disease is a topic that will never go out of style. The philosophy and approach to treatment has deepened and even modified as our understanding of the disease has grown. Each medication has its own advantages and disadvantages and requires a careful mix of specialists in its use in order to build on its strengths and avoid its weaknesses. It can be said that the treatment of Parkinson’s disease is a skill, but also an art! Parkinson’s disease is a neurodegenerative disease characterized by neurodegenerative lesions in the striatal pathway of the substantia nigra, and the incidence of PD is about 1% to 2% in people over 60 years old, making it the second most serious neurodegenerative disease affecting human health. I. Drugs to increase dopamine content (i) Dope-based agents: PD symptoms are mainly due to dopamine deficiency, so dopamine replacement therapy is effective. Levodopa has become the main therapeutic drug for PD motor symptoms and is the basic drug for PD. Currently, the main clinical applications are compound preparations of levodopa, such as levodopa with benserazide, compound levodopa controlled-release tablets, levodopa with carbidopa orally disintegrating tablets, and extended-release capsule preparations, with the aim of reducing adverse effects while allowing a significant increase in the dose of levodopa reaching brain tissue. Compound levodopa normal release has a fast onset of action, while controlled release has a relatively long maintenance time, but a slow onset of action and low bioavailability. patients with PD may experience a decrease in efficacy after a longer period of treatment, as evidenced by fluctuations in symptoms and end-of-dose deterioration. The number of doses of compounded levodopa may be increased by reducing the single dose and also by switching to levodopa controlled-release tablets to alleviate dyskinesia. Available evidence suggests that early application of small doses (≤400 mg/d) of levodopa combination does not increase the occurrence of isokinetic disorders, but after 4-6 years of levodopa combination treatment for PD, 40% to 70% of patients still experience complications such as symptom fluctuations and dyskinesia. The therapeutic strategy of continuous dopaminergic stimulation is the latest advancement in PD treatment concept in recent years, and is expected to solve the difficulties that plague PD patients such as motor fluctuations. (B) Drugs to increase the bioavailability of dopamine in the brain: Two enzymes are required for dopamine degradation, namely MAO and COMT. MAO inhibitors are represented by selagiline and resagiline, which can be used alone or in combination with compounded levodopa preparations, and the combined application can delay the appearance of motor complications and reduce levodopa dosage. Resagiline is easy to apply and has good compliance, but should be used with caution in patients with gastric ulcer and is prohibited to be combined with 5-hydroxytryptamine reuptake inhibitors. COMT inhibitors are represented by entacapone and tolcapone, which can only be combined with compounded levodopa preparations. Entacapone can be used in PD patients with “end-of-dose phenomenon” to increase the “on phase” and decrease the “off phase” and to improve the UPDRS motor score. The most common adverse effect is allodynia, followed by gastrointestinal dysfunction and change in urine color. Second, to improve the dopamine receptor function of drugs: dopamine receptor stimulants (dopamine agonists, DAs), the representative drugs are pramipexole, piribedil, ropinirole, rotigotine transdermal patch. In particular, the drug can be used alone in early, younger PD patients. One of the advantages of the commonly used DAs is their long half-life and better stimulation of dopamine receptors than the “pulse-like stimulation” of compound levodopa, which is a continuous dopaminergic stimulation (CDS) close to the physiological state. Other drugs and adjuvant medications: (a) Amantadine: It can be considered for patients with all stages of PD. It can be used in patients with predominantly tremor or tonicity, or in patients with motor complications on long-term medication, the addition of amantadine can reduce levodopa dosage and thus reduce motor complications. Adverse effects include hallucinations, mood changes, etc. (B) Anticholinergic drugs: Benzhexol hydrochloride is mainly used for patients with tremor, especially for patients under 65 years of age with significant tremor when other anti-PD drugs are not effective. It is generally not used in patients without tremor, especially in elderly male patients over 65 years of age. Closed-angle glaucoma and prostatic hypertrophy are prohibited. (C) Other drugs such as iron chelators and coenzyme Q10 have neuroprotective effects can be used in PD treatment. After continuous exploration, the drug treatment of Parkinson’s disease has made great progress, but at present Parkinson’s disease is still incurable. It is believed that with the deepening understanding of the disease, the development of new drugs, breakthroughs in new dosage forms and the emergence of new drug delivery methods, the drug treatment of Parkinson’s disease will make greater progress.